Apellis Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining 2025 performance ...

In a preliminary report of its 2025 results, Apellis said that sales of its geographic atrophy (GA) drug Syfovre came in at ...

Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for geographic atrophy (GA), Syfovre, may have hit a performance “nadir” in 2024’s ...

On Tuesday, JP Morgan highlighted its survey related to Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Syfovre and Astellas Pharma Inc’s (OTC:ALPMF) (OTC:ALPMY) Izervay. On average, surveyed physicians ...

WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that SYFOVRE ® (pegcetacoplan injection) preserved visual function at 36 months in patients with ...

Please provide your email address to receive an email when new articles are posted on . Six cases of intraocular inflammation and retinal vasculitis have been reported. Retina specialists should ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Apellis is exclusively distributing injection kits with ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a second quarter (Q2) EPS loss of $1.02, beating the consensus of -$1.35. Sales came in at $95 million, up from $16.3 million a year ago, beating the ...